# Progress Note 06 — Preventive Visit

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Howard Hughes (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML006-SYN-TD
- Date: 1947-09-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Anselm Garrity-Moyo, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Preventive Visit
- Services: CPT 99396 (periodic preventive medicine, established patient, age 40 to 64) with CPT 99497 (advance care planning), both on the same day

## Chief complaint

Periodic adult preventive visit. **S**

## History of present illness

Mr. Hughes is a 41-year-old man with obsessive-compulsive disorder on sertraline 200 mg and exposure and response prevention, opioid use disorder on buprenorphine with naloxone, chronic pain after a plane crash, and noise-induced hearing loss with new hearing aids, who comes for his yearly preventive visit three weeks before his twenty-two-week review. He completed the health risk assessment in the waiting room, which he could not have done at intake, and sat in the shared chairs. His washing and checking now take about one and a half hours a day. He has used no opioid other than buprenorphine. He wears his hearing aids every day. He has had no fever or cough since his bronchitis cleared. He cannot recall any vaccines since the crash. **S**

| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 41 |
| OCD | Rituals about one and a half hours a day; Y-BOCS 17 today |
| Opioids | Buprenorphine 8 mg twice daily; no other opioid use |
| Mood | PHQ-2 0 |
| Medicines | Sertraline 200 mg daily; buprenorphine with naloxone 8 mg twice daily; acetaminophen 1,000 mg three times daily; naloxone nasal spray on hand |

## Health risk assessment

Completed on paper in the waiting room and reviewed with the patient by Dr. Garrity-Moyo. **S**

| Domain | Finding |
|---|---|
| Self-rated health | Good, and better than in the spring |
| Psychosocial | Weekly exposure therapy; working longer days; still prefers to meet few people |
| Substance use | In treatment for opioid use disorder on buprenorphine; AUDIT-C 1 at intake |
| Tobacco | Never smoked |
| Physical activity | Physical therapy exercises daily and walks most days |
| Nutrition | Three meals a day, including food his cook prepares without his watching |
| Sleep | Six to seven hours |
| Safety at home | Feels safe; no firearms in the home; naloxone in the house |
| Road and air safety | Wears a seat belt; wears hearing protection when flying |
| Activities of daily living | Independent |
| Hearing and vision | Hearing aids daily; no vision problems |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or night sweats; weight rising as planned |
| Eyes | Negative | No vision change |
| Ears, nose, mouth, and throat | Positive | Hearing loss, helped by hearing aids; no tinnitus or ear pain |
| Cardiovascular | Negative | No chest pain apart from the old chest wall pain, no palpitations |
| Respiratory | Negative | Cough resolved; no shortness of breath |
| Gastrointestinal | Negative | No constipation on buprenorphine; no blood in the stool |
| Genitourinary | Negative | No urinary symptoms |
| Musculoskeletal | Positive | Chest wall, left shoulder and low back pain, milder than in the spring |
| Skin | Negative | Hands no longer cracked from washing |
| Neurological | Negative | No headaches, weakness or numbness |
| Psychiatric | Positive | Contamination fears milder; mood good; no thoughts of suicide or of harming anyone |

11 systems reviewed. **S**

## Current medications

- Naloxone 4 mg nasal spray, one spray into one nostril for a suspected opioid overdose, repeated every two to three minutes in the other nostril if needed; two-pack dispensed, with instruction for him and his household staff **S**
- Buprenorphine 8 mg with naloxone 2 mg sublingual film, one film twice daily (16 mg a day), for opioid use disorder and pain; dispensed one week at a time at first **S**
- Acetaminophen 500 mg oral tablet, two tablets three times daily (3,000 mg a day) for pain after the crash, now that codeine combination tablets have stopped **S**
- Sertraline 100 mg oral tablet, two tablets daily (200 mg), the usual target range for OCD **S**

## Allergies

- No known allergy **S**

## Objective

BP 116/74 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 75.6 kg; BMI 20.7 kg/m². All vital signs are synthetic.

Total cholesterol: 182 mg/dL; HDL cholesterol: 52 mg/dL; LDL cholesterol (calculated): 112 mg/dL; Triglycerides: 90 mg/dL; PHQ-2: 0. All results are synthetic.

## Immunizations given today

- Influenza vaccine for the coming season **S**
- Tdap vaccine; no tetanus booster recorded since the crash **S**
- Hepatitis B vaccine (HepB-CpG), first of two doses; not immune at intake **S**

## Physical examination

| System | Finding |
|---|---|
| Constitutional | Well; weight 75.6 kg, BMI 20.7; blood pressure 116/74; pulse 70 |
| Ears, nose, mouth, and throat | Hearing aids in place; canals clear; teeth and gums healthy |
| Neck | No thyroid enlargement or nodes |
| Cardiovascular | Regular rhythm; no murmur |
| Respiratory | Clear to auscultation; healed scars on the chest wall |
| Abdomen | Soft and non-tender |
| Skin | Healed burn scars; hands no longer cracked |
| Psychiatric | Calm and engaged; shook hands at the end of the visit |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Periodic adult preventive visit completed**. Health risk assessment reviewed and the prevention plan updated. HIV, hepatitis C and hepatitis B tests at intake were negative, and he is not immune to hepatitis B. Fasting lipids today: total cholesterol 182, HDL 52, LDL 112 and triglycerides 90 mg/dL; his 10-year cardiovascular risk is low, so no statin. Colorectal cancer screening begins at 45, and diabetes screening is not indicated with a normal weight. **S**
   - Repeat lipids in five years.
   - Next preventive visit in one year.
2. **Obsessive-compulsive disorder, improving** (F42.2). Y-BOCS 17, down from 28. He used the waiting room chairs and the shared pen as exposure exercises. Safety reviewed: no thoughts of suicide or of harming anyone. **S**
   - Continue sertraline 200 mg and weekly exposure and response prevention.
3. **Opioid use disorder on buprenorphine** (F11.20). Stable on buprenorphine 8 mg twice daily; no other opioid use. **S**
   - Continue buprenorphine; naloxone at home.

## Personalized prevention plan

A written copy was given to the patient. **S**

| Service | Status | Detail |
|---|---|---|
| Blood pressure | Completed today | 116/74 mmHg |
| Lipid screening and cardiovascular risk | Completed today | LDL 112 mg/dL; low 10-year risk; statin not indicated |
| Diabetes screening | Not indicated | Recommended for adults 35 to 70 with overweight or obesity; his BMI is 20.7 |
| Colorectal cancer screening | Not indicated | Begins at 45; no family history recorded |
| Lung cancer screening | Not indicated | Never smoked |
| HIV screening | Up to date | Negative at intake |
| Hepatitis C screening | Up to date | Antibody negative at intake |
| Hepatitis B screening | Up to date | Triple panel at intake: not infected and not immune |
| Depression screening | Completed today | PHQ-2 0 |
| Unhealthy drug use | Up to date | In treatment for opioid use disorder |
| Unhealthy alcohol use | Up to date | AUDIT-C 1 at intake; advised to keep alcohol low with buprenorphine |
| Hearing | Up to date | Audiogram at five weeks; hearing aids fitted at ten weeks |
| Influenza vaccine | Completed today | Vaccine for the coming season given today |
| Tetanus, diphtheria, and pertussis | Completed today | Tdap today; no booster recorded since the crash |
| Hepatitis B vaccine | Completed today | First of two HepB-CpG doses; second in one month or more |
| COVID-19 vaccine | Due | Recommended for the coming season; he chose to have it at his next visit rather than a fourth injection today |

## Advance care planning

Voluntary advance care planning discussion of about 16 minutes, with his consent. He named a health care agent and completed a health care proxy form; the agent is recorded in the chart and is not named here. He said that what matters most to him is privacy, being able to work, and making his own decisions. He would want full treatment for any condition from which he could recover and to be told plainly about his health. He chose not to record other preferences today. The plan will be revisited yearly or after any serious illness or injury. **S**

## Guideline basis

- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge
- Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026), Aether Forge
- USPSTF A and B Recommendations (2026), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Twenty-two-week review in three weeks with laboratory tests. Second hepatitis B dose in one month or more; COVID-19 vaccine at the next visit. Next preventive visit in one year. **S**
- Next scheduled visit 1947-10-05: twenty-two-week review: response of OCD, buprenorphine maintenance, pain, weight and laboratory checks. **S**
